Development of lipid nanoparticles for transdermal loteprednol etabonate delivery

Uner B., Ozdemir S., Tas C., ERGİNER Y., Uner M.

JOURNAL OF MICROENCAPSULATION, vol.39, no.4, pp.327-340, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 39 Issue: 4
  • Publication Date: 2022
  • Doi Number: 10.1080/02652048.2022.2079744
  • Journal Name: JOURNAL OF MICROENCAPSULATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.327-340
  • Keywords: Loteprednol etabonate, nanostructured lipid carriers, solid lipid nanoparticles, topical corticosteroids, transdermal delivery, TOPICAL APPLICATION, DRUG PENETRATION, WATER EMULSION, SKIN, STABILIZATION, LOCALIZATION, FORMULATIONS, PERMEATION, MANAGEMENT, STABILITY
  • Istanbul University Affiliated: Yes

Abstract

Aim Loteprednol etabonate (LE) is a new generation corticosteroid that is used for the treatment of inflammatory and allergic conditions of the eye. Therefore, solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) were attempted to improve transdermal LE delivery for the first time. Methods SLN and NLC were produced by hot homogenisation and ultrasonication technique. Their physical stability was monitored for 3 months of storage. Drug release and permeation of SLN and NLC through the porcine skin were investigated. Results It was determined that SLN and NLC mean particle size of 139.1 nm had a homogeneous particle size distribution (similar to 0.169 PI) and the mean charge was -23.6. They were found to be stable both physically and chemically at room temperature. Conclusion SLN and NLC formulations of LE can be stated among the systems that can be an alternative to conventional systems with fewer side-effects in the treatment of inflammatory problems.